796 reports of this reaction
3.2% of all RIZATRIPTAN BENZOATE reports
#5 most reported adverse reaction
OFF LABEL USE is the #5 most commonly reported adverse reaction for RIZATRIPTAN BENZOATE, manufactured by Organon LLC. There are 796 FDA adverse event reports linking RIZATRIPTAN BENZOATE to OFF LABEL USE. This represents approximately 3.2% of all 24,816 adverse event reports for this drug.
Patients taking RIZATRIPTAN BENZOATE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among RIZATRIPTAN BENZOATE users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for RIZATRIPTAN BENZOATE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 796 FDA reports for RIZATRIPTAN BENZOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.2% of all adverse event reports for RIZATRIPTAN BENZOATE, making it a notable side effect.
If you experience off label use while taking RIZATRIPTAN BENZOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.